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AbstrAct
Objective
To characterise the clinical features of children and 
young people admitted to hospital with laboratory 
confirmed severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection in the UK and 
explore factors associated with admission to critical 
care, mortality, and development of multisystem 
inflammatory syndrome in children and adolescents 
temporarily related to coronavirus disease 2019 
(covid-19) (MIS-C).
Design
Prospective observational cohort study with  
rapid data gathering and near real time analysis.
setting
260 hospitals in England, Wales, and Scotland 
between 17 January and 3 July 2020, with a 
minimum follow-up time of two weeks (to 17 July 
2020).
ParticiPants
651 children and young people aged less than 19 
years admitted to 138 hospitals and enrolled into the 
International Severe Acute Respiratory and emergency 
Infections Consortium (ISARIC) WHO Clinical 
Characterisation Protocol UK study with laboratory 
confirmed SARS-CoV-2.
Main OutcOMe Measures
Admission to critical care (high dependency or 
intensive care), in-hospital mortality, or meeting the 
WHO preliminary case definition for MIS-C.
results
Median age was 4.6 (interquartile range 0.3-13.7) 
years, 35% (225/651) were under 12 months old, 
and 56% (367/650) were male. 57% (330/576) 
were white, 12% (67/576) South Asian, and 10% 
(56/576) black. 42% (276/651) had at least one 
recorded comorbidity. A systemic mucocutaneous-
enteric cluster of symptoms was identified, which 
encompassed the symptoms for the WHO MIS-C 
criteria. 18% (116/632) of children were admitted 
to critical care. On multivariable analysis, this was 
associated with age under 1 month (odds ratio 3.21, 
95% confidence interval 1.36 to 7.66; P=0.008), 
age 10-14 years (3.23, 1.55 to 6.99; P=0.002), and 
black ethnicity (2.82, 1.41 to 5.57; P=0.003). Six 
(1%) of 627 patients died in hospital, all of whom 
had profound comorbidity. 11% (52/456) met the 
WHO MIS-C criteria, with the first patient developing 
symptoms in mid-March. Children meeting MIS-C 
criteria were older (median age 10.7 (8.3-14.1) v 1.6 
(0.2-12.9) years; P<0.001) and more likely to be of 
non-white ethnicity (64% (29/45) v 42% (148/355); 
P=0.004). Children with MIS-C were five times more 
likely to be admitted to critical care (73% (38/52) 
v 15% (62/404); P<0.001). In addition to the WHO 
criteria, children with MIS-C were more likely to 
present with fatigue (51% (24/47) v 28% (86/302); 
P=0.004), headache (34% (16/47) v 10% (26/263); 
P<0.001), myalgia (34% (15/44) v 8% (21/270); 
P<0.001), sore throat (30% (14/47) v (12% (34/284); 
P=0.003), and lymphadenopathy (20% (9/46) v 3% 
(10/318); P<0.001) and to have a platelet count of 
less than 150 × 109/L (32% (16/50) v 11% (38/348); 
P<0.001) than children who did not have MIS-C. No 
deaths occurred in the MIS-C group.
cOnclusiOns
Children and young people have less severe acute 
covid-19 than adults. A systemic mucocutaneous-
enteric symptom cluster was also identified in acute 
cases that shares features with MIS-C. This study 
provides additional evidence for refining the WHO 
MIS-C preliminary case definition. Children meeting 
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WhAt is AlreAdy knoWn on this topic
Less information on ethnicity, comorbidities, and clinical and laboratory findings 
is available in children with SARS-CoV-2 than in adults
A multisystem inflammatory syndrome in children and adolescents (MIS-C) 
temporally associated with SARS-CoV-2 has been widely reported
However, all reports to date arise from retrospective cases series that are 
vulnerable to ascertainment, selection, and recall bias
WhAt this study Adds
Severe disease was rare and death exceptionally rare in this is a large 
prospective cohort study of children admitted to hospital with laboratory 
confirmed covid-19
Ethnicity seems to be a factor in both critical care admission and MIS-C
This cohort has enabled identification of additional clinical and laboratory 
characteristics that should help to refine the WHO criteria for MIS-C
 o
n
 9 O
ctober 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m3249 on 27 August 2020. Downloaded from 
RESEARCH
2 doi: 10.1136/bmj.m3249 | BMJ 2020;370:m3249 | the bmj
the MIS-C criteria have different demographic and 
clinical features depending on whether they have 
acute SARS-CoV-2 infection (polymerase chain 
reaction positive) or are post-acute (antibody 
positive).
stuDy registratiOn
ISRCTN66726260.
introduction
Children and young people comprise only 1-2% 
of cases of coronavirus disease 2019 (covid-19) 
worldwide.1-3 In contrast to other respiratory viruses, 
children seem to have a lower risk of infection than 
adults,4 and the vast majority of reported infections in 
children are mild or asymptomatic, with few recorded 
childhood fatalities attributed to covid-19.2 5-7 Initial 
reports from China showed that only 0.6% of children 
with covid-19 were critically ill.5
A severe disease phenotype has emerged in children 
that seems to be temporally associated with severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection.8 9 The condition was first described 
in May 2020 in a cluster of children admitted to 
critical care in south London (UK), with evidence 
of a multisystem hyperinflammatory state with 
features similar to Kawasaki disease and toxic shock 
syndrome.8 These children needed inotropic support 
for refractory circulatory shock and mechanical 
ventilation for cardiovascular stabilisation rather 
than respiratory failure. Similar cohorts have been 
reported in Italy and France.10 11 The European Centre 
for Disease Prevention and Control estimated on 15 
May 2020 that around 230 children had presented 
with this new syndrome in EU/EEA countries, with 
two fatalities.3 The World Health Organization and the 
Royal College of Paediatrics and Child Health (RCPCH) 
have proposed preliminary case definitions.9 12 WHO 
uses the term multisystem inflammatory syndrome 
in children and adolescents temporarily related to 
covid-19 (MIS-C), and the RCPCH describes this illness 
as paediatric inflammatory multisystem syndrome 
temporally associated with SARS-CoV-2 (PIMS-TS).
We aimed to characterise the features of children and 
young people (aged <19 years) admitted to hospital in 
the UK with laboratory confirmed SARS-CoV-2 infection 
from the International Severe Acute Respiratory and 
emerging Infection Consortium (ISARIC) WHO Clinical 
Characterisation Protocol UK (CCP-UK) cohort. As 
our study enrolled patients prospectively from the 
beginning of the pandemic, we also had a unique 
opportunity to examine the emergence, timing, risk 
factors, clinical presentation, progression, course, and 
outcomes of children and young people meeting the 
WHO preliminary case definition for MIS-C.9
Methods
study design and setting
The ISARIC WHO CCP-UK is an ongoing prospective 
cohort study across acute care hospitals in England, 
Wales, and Scotland.13 This standing protocol for 
studying disease caused by pathogens of public 
health interest was activated on 17 January 2020. 
The protocol, associated documents, and details of 
the Independent Data and Material Access Committee 
(IDAMAC) are available at https://isaric4c.net. We 
used STROBE guidelines when reporting.
Participants
Patients of any age admitted to hospital with proven or 
high likelihood of SARS-CoV-2 infection were enrolled 
into the ISARIC WHO CCP-UK cohort as previously 
described.13 We present the data from children and 
young people aged less than 19 years on the date 
of hospital admission, enrolled into the study up 
to and including 3 July 2020, who had at least two 
weeks of outcome data available. For this report, we 
included only those children and young people who 
had documented laboratory evidence of SARS-CoV-2 
infection (by polymerase chain reaction or serology). 
Patients were admitted to hospital or critical care at the 
discretion of the clinical team caring for them, and we 
set no criteria for these. We also included patients who 
were already admitted for other clinical reasons and 
subsequently tested positive for SARS-CoV-2 while an 
inpatient.
Data collection
Demographic and baseline data (including comor-
bidities and regular medications taken) alongside 
data on symptoms, clinical signs (including vital 
signs) during admission, laboratory and pathology 
investigations, treatments received while admitted, 
and outcome were collected onto case report forms 
(see supplementary methods). Data on illness 
progression and severity, including location within 
the hospital (ward versus critical care), were collected 
on day 1 (admission/diagnosis), day 3, day 6, day 
9, admission to critical care, and discharge/death. 
Data were collected from healthcare records onto the 
case report forms through a secure online database, 
REDCap (Research Electronic Data Capture, Vanderbilt 
University, hosted by the University of Oxford). 
Collection of this routine anonymised demographic 
and clinical data from medical records did not require 
consent in England and Wales. In Scotland, a waiver 
for consent was obtained from the Public Benefit and 
Privacy Panel.
variables
The case report form was agnostic to patients’ age, so 
existing comorbidity variables were not tailored to the 
paediatric population (see supplementary methods for 
case report form and recoding of paediatric variables). 
Ethnicity was self-reported and transcribed from the 
healthcare record. The Paediatric Early Warning Score 
(PEWS) was used as a measure of disease severity at 
admission.14
criteria for diagnosis of Mis-c
We used the WHO preliminary case definition for 
MIS-C as a framework for identifying children with the 
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syndrome within this dataset (box 1),9 with adaptations 
defining thresholds to allow case identification in the 
ISARIC WHO CCP-UK cohort.
Duplicates
For cases in which a child appeared twice in the dataset 
(that is, by readmission or transfer between two 
recruiting centres), we retained only one admission in 
the data (detailed in supplementary methods).
Outcomes
The primary outcomes of this study were admission 
to critical care (high dependency unit or paediatric 
intensive care unit), development of MIS-C, and in-
hospital mortality. Paediatric intensive care units are 
dedicated care settings providing the highest level 
of critical care for children and young people, who 
usually need invasive ventilation or support for two 
or more organs with a higher nurse to patient ratio. 
Paediatric intensive care units are usually located 
in regional tertiary centres or specialised hospitals. 
Paediatric high dependency units are for patients 
needing close monitoring and therapies for organ 
support without invasive ventilation or intensive care 
and are provided at tertiary hospitals and a limited 
number of district general hospitals.19 Admission to 
critical care is governed by the degree of physiological 
instability rather than diagnosis. We also examined 
need for respiratory and cardiovascular support. A 
minimum two week follow-up was ensured for all 
included patients.
bias and missing data
Specialist children’s hospitals (tertiary care) with 
paediatric specific research teams and paediatric 
intensive care units may be over-represented. Capacity 
to enrol was also limited by staff resources at times of 
high covid-19 activity, and we were unable to comment 
on patients who were not recruited.
The pandemic disrupted routine care and usual 
research activities, limiting data collection and 
verification, particularly during the peak of outbreak 
activity. We did not impute missing data for this 
descriptive analysis. To reduce the effect of missing 
data on outcome analyses, we restricted these analyses 
to patients who had been admitted for at least two 
weeks before data extraction. Complete data were 
not available for all variables, so denominators differ 
between analyses.
statistical analysis
Continuous variables are shown as mean (standard 
deviation) or as median (interquartile range) if 
non-normally distributed. Categorical variables are 
presented as a frequency (percentage) unless other-
wise stated. For univariable comparisons, we used 
Welch’s t, analysis of variance, Mann-Whitney U, or 
Kruskal-Wallis tests, according to data distribution. 
We compared categorical data by using χ2 tests and 
considered a P value below 0.05 to be statistically 
significant; all tests were two sided. We made no 
adjustment for multiple comparisons. Parsimonious 
criterion based model building used the following 
principles: relevant explanatory variables were identi-
fied from previous studies; interactions were checked 
at first order level; final model selection was informed 
by the Akaike information criterion and C statistic, 
with appropriate assumptions checked including the 
distribution of residuals. Analysis of symptom co-
occurrence used the Jaccard similarity coefficient and 
was presented as a hierarchically ordered heatmap 
(supplementary methods). We used R (R Core Team 
version 3.6.3, Vienna, Austria) for statistical analyses, 
with packages including tidyverse, finalfit lubridate, 
ggplot2, gplot, mclust, dendextend, and UpSetR.
Patient and public involvement
This was an urgent public health research study in 
response to a public health emergency of international 
concern. Patients and the public were not involved in 
the design, conduct, or reporting of this rapid response 
research.
results
Between 17 January and 3 July 2020, 69 516 patients 
of all ages (range 0-106 years) were enrolled at 260 
hospitals across England, Scotland, and Wales. Of 
these, 651 were patients under 19 years old with 
laboratory confirmed SARS-CoV-2 (651/69 516 
(0.9%) of the total cohort (table 1; supplementary 
figures A and B). These patients were enrolled across 
138 sites, of which 20 had a paediatric intensive care 
unit. We recruited 55 patients as hospital inpatients; 
they had been admitted for more than five days before 
symptom onset, indicating likely hospital acquired 
infection.
box 1: WHO preliminary case definition for Mis-c, with adaptations (italics) 
defining thresholds to allow case identification in isaric WHO ccP-uK cohort
1. Fever for 3 days or more (of any duration, self-reported before presentation)
2. Plus two of the following:
a. Rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammatory 
signs (self-reported rash/conjunctivitis)
b. Hypotension or shock (age <2 years, systolic blood pressure <60 mm Hg; ≥2 and 
<5 years, <70 mm Hg; ≥5 and <12 years, <80 mm Hg; ≥12 years, <90 mm Hg at any 
point in admission14)
c. Features of myocardial dysfunction, pericarditis, valvulitis, or coronary 
abnormalities (diagnosis of endocarditis or myocarditis or documented 
pericardial effusion, coronary artery aneurysm, cardiomegaly, or cardiac 
dysfunction on echocardiography)
d. Evidence of coagulopathy (international normalised ratio >1.2 (any 
age),premature neonate with prothrombin time >16 s15 or term infant/older child 
with prothrombin time >14 s16-18 (see supplementary methods))
e. Acute gastrointestinal problems (self-reported diarrhoea, vomiting, or 
abdominal pain)
3. Plus elevated markers of inflammation (C reactive protein ≥60 mg/L or ferritin ≥200 
mg/L at any point during admission; cut-offs chosen after expert discussion)
4. Plus no other obvious microbial cause of inflammation (no significant positive 
growth on blood culture/cerebrospinal fluid culture during admission)
 o
n
 9 O
ctober 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m3249 on 27 August 2020. Downloaded from 
RESEARCH
4 doi: 10.1136/bmj.m3249 | BMJ 2020;370:m3249 | the bmj
age, sex, and ethnicity
The median age of the children was 4.6 (interquartile 
range 0.3-13.7) years, 35% (225/651) were under 12 
months old, and 56% (367/650) were male (table 1). 
Ethnicity was recorded in 88% (576/651) of cases: 
57% (330/576) were white, 12% (67/576) were South 
Asian, and 10% (56/576) were of black ethnicity. At 
least one comorbidity was reported in 42% (276/651) 
of cases.
symptoms
The most common presenting symptoms were fever 
(70%; 431/617), cough (39%; 233/599), nausea/
vomiting (32%; 179/564), and shortness of breath 
(30%; 173/570) (fig 1). Fever and rhinorrhoea were 
less common with increasing age; however, nausea and 
vomiting, abdominal pain, headache, and sore throat 
showed an increasing trend with age (supplementary 
figure D). A heatmap and dendrogram of presenting 
symptoms showed three distinct clusters of clinical 
phenotypes (fig 2). These comprised most commonly 
a discrete respiratory illness (green cluster) of cough, 
fever, shortness of breath, runny nose, lower chest 
wall indrawing, and wheeze, with clustering of both 
upper and lower respiratory symptoms together. Next 
was a cluster representing a systemic mucocutaneous-
enteric illness (purple cluster) of headache, myalgia, 
sore throat, vomiting, abdominal pain, diarrhoea, 
fatigue, rash, lymphadenopathy, and conjunctivitis. 
Finally, we observed a rarer neurological cluster of 
seizures and confusion (red cluster). The systemic 
mucocutaneous-enteric cluster includes the symptoms 
specified in the WHO preliminary case definition for 
MIS-C (“muco-cutaneous inflammation” and “acute 
gastrointestinal problems”), in addition to sore throat, 
myalgia, headache, and fatigue. The two main clusters 
“respiratory” and “systemic mucocutaneous-enteric” 
were not entirely dichotomous. Minor overlap occurred 
between a sub-cluster of “fever, cough, and shortness 
of breath” and a sub-cluster of “vomiting, abdominal 
pain, diarrhoea, fatigue, and rash” but very little 
overlap with “runny nose, wheeze, and lower chest 
wall indrawing.”
comorbidities
The most common comorbidities were neurological 
(11%; 65/614), haematological/oncological/immuno 
logical (combined category as described in supple-
mentary methods: 8%; 48/615), and asthma (7%; 
45/615). Data on prematurity (defined as birth before 
completion of 37 weeks’ gestation) were as usual 
routinely collected only for children aged under 1 
year, and 23% (46/201) were premature (table 1, 
supplementary table A, and supplementary figure C).
The median PEWS at presentation was 3 
(interquartile range 1.0-5.0), and median blood test 
results at presentation were mostly within normal 
ranges (supplementary tables B and C). Antibiotics were 
given to 69% (415/601) of children, and 6% (38/591) 
received antiviral drugs (30 received acyclovir, 7 
received remdesivir, and 3 received chloroquine/
hydroxychloroquine, some in combination) (table 2).
children needing critical care
Eighteen per cent (116/632) of children were admitted 
to critical care (intensive care unit or high dependency 
unit level care); 8% (47/597) received inotropic support, 
9% (57/619) received non-invasive ventilation, and 
9% (58/620) received invasive mechanical ventilation 
(table 2, table 3, and supplementary figure E). Black 
ethnicity was significantly associated with admission 
to critical care on multivariable analysis (odds ratio 
2.82, 95% confidence interval 1.41 to 5.57; P=0.003) 
(table 4 and supplementary table D). On multivariable 
analysis, both age under 1 month (odds ratio 3.21, 
1.36 to 7.66; P=0.008) and age between 10 and 14 
years (3.23, 1.55 to 6.99; P=0.002) were associated 
table 1 | Demographics across cohort of patients under 19 years with laboratory 
confirmation of sars-cov-2. values are numbers (percentages) unless stated otherwise
variable Patients (n=651)
Median (interquartile range) age, years 4.6 (0.3-13.7)
Age group:
 <1 month 53 (8.1)
 1 month to <1 year 172 (26.4)
 1-4 years 108 (16.6)
 5-9 years 92 (14.1)
 10-14 years 94 (14.4)
 15-19 years 132 (20.3)
Sex at birth:
 Male 367 (56.4)
 Female 283 (43.5)
 Missing 1 (0.2)
Ethnicity:
 White 330 (50.7)
 Black 56 (8.6)
 South Asian 67 (10.3)
 Other 123 (18.9)
 Missing 75 (11.5)
Admitted >5 days before symptom onset:
 No 538 (82.6)
 Yes 55 (8.4)
 Missing 58 (8.9)
Any comorbidity:
 No/unknown 375 (57.6)
 Yes 276 (42.4)
Neurological comorbidity:
 No 549 (84.3)
 Yes 65 (10.0)
 Missing 37 (5.7)
Haematological, oncological, immunological comorbidity:
 No 567 (87.1)
 Yes 48 (7.4)
 Missing 36 (5.5)
Asthma:
 No 570 (87.6)
 Yes 45 (6.9)
 Missing 36 (5.5)
Prematurity*:
 No 155 (23.8)
 Yes 46 (7.1)
 Missing 450 (69.1)
Immunosuppressant use before presentation†:
 No 546 (83.9)
 Yes 53 (8.1)
 Missing 52 (8.0)
*Defined as birth before completion of 37 weeks’ gestation.
†Includes oral but not inhaled corticosteroids.
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with admission to critical care (reference age group 
15-19 years), but we found no association with sex on 
either univariable or multivariable analysis (table 3, 
table 4, and supplementary table D).
On univariable analysis, children with comorbidities 
were more likely to be admitted to critical care than 
those without comorbidities (odds ratio 1.73, 1.15 
to 2.60; P=0.008); however, this no longer reached 
significance in the multivariable model (odds ratio 
1.42, 0.89 to 2.28; P=0.141). Comorbidities most 
commonly associated with critical care admission on 
univariable analysis were prematurity (50% (15/30) 
of critical care admissions v 18% (30/165) of standard 
care admissions; P=0.001), respiratory comorbidities 
(10% (12/115) v 4% (21/491); P=0.019), cardiac 
comorbidities (13/115 (11%) v 25/493 (5%); 
P=0.018), and obesity (6% (7/115) v 2% (10/487); 
P=0.028) (table 3 and supplementary table E). Children 
receiving critical care were more likely to have been 
admitted to hospital more than five days before their 
symptoms started (indicating likely hospital acquired 
infection) than those receiving ward level care (16% 
(18/110) v 8% (36/473); P=0.009). We found no 
association between previous immunosuppressant use 
and critical care admission (table 3).
Children admitted to critical care were more likely to 
have presented with diarrhoea, (38% (40/104) v 13% 
(58/448); P<0.001), conjunctivitis (16% (16/100) v 
2% (10/412); P<0.001), and altered consciousness/
confusion (19% (19/99) v 6% (24/434); P<0.001) than 
those cared for on a standard ward (supplementary 
table F). They were objectively more unwell at 
presentation than those receiving standard ward care 
(median PEWS of 5 (2.0-7.0) v 2 (1.0-4.0); P<0.001) 
(supplementary table G). We also observed significant 
differences in haematological, biochemical, and 
radiological abnormalities between the two groups at 
presentation (supplementary table H). In particular, 
children admitted to critical care had a lower platelet 
count (median 192.0×109/L (interquartile range 133.0-
280.5×109/L) v 296.5×109/L (229.0-383.5×109/L); 
P<0.001), a higher neutrophil count (7.7×109/L (4.3-
12.3×109/L) v 4.6×109/L (2.3-8.2×109/L); P<0.001), 
and higher C reactive protein (64.5 (11.1-200.2) mg/L 
v 11.0 (3.0-54.5) mg/L; P<0.001) at presentation than 
those cared for on a standard ward. Children admitted 
to critical care were also more likely to have infiltrates 
on a chest radiograph (58% (47/81) v 32% (52/162); 
P<0.001).
We did a sub-analysis for critical care admission 
excluding any children who met the criteria for MIS-C. 
In this subgroup, the associations described above 
persisted, although obesity was no longer significantly 
associated with critical care admission (supplementary 
table I). In patients without MIS-C, prematurity and 
respiratory and cardiac comorbidities remained 
significantly associated with admission to critical 
care in addition to neurological (22% (17/77) v 10% 
(46/481); P=0.003), neurodisability (13% (9/71) v 5% 
(22/463); P=0.014), and gastrointestinal (9% (7/77) v 
2% (11/480); P=0.007) comorbidities (supplementary 
table J), as is generally the case for children and young 
people most at risk of admission to critical care. After 
exclusion of children with MIS-C, conjunctivitis and 
diarrhoea were no longer significantly associated 
with critical care admission (supplementary table 
K); instead, shortness of breath (44% (31/71) v 28% 
(123/445); P=0.008) was associated with critical 
care admission. Total PEWS at presentation remained 
associated with critical care admission (supplementary 
table L). As expected, when cases of MIS-C were 
excluded, blood tests in patients admitted to critical 
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Fig 1 | Proportion of patients presenting with each symptom
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care showed less of an inflammatory pattern compared 
with those cared for on a standard ward (median 
neutrophils 6.2×109/L (3.4-9.6×109/L) in critical 
care admissions versus 4.5×109/L (2.3-8.2×109/L) in 
standard ward admissions (P=0.059) and median C 
reactive protein 21.4 (5.0-51.9) mg/L v 9.0 (3.0-46.9) 
mg/L (P=0.069)) (supplementary table M).
Outcomes
Outcome data were available for 627 children 
(table 2). Six (1%) children and young people died 
in hospital. Three were neonates (age <28 days) 
with severe comorbidities/illness—very premature, 
complex congenital cardiac anomaly, and bacterial 
sepsis. Three were aged 15-18 years, two of whom had 
profound neurodisability with pre-existing respiratory 
compromise; the other was immunosuppressed by 
chemotherapy for malignancy and had bacterial 
sepsis. Two children under 5 years old, both with life 
limiting, complex comorbidities, were discharged with 
planned palliative care and cause of death was not 
related to covid-19. Eighty nine per cent (557/627) of 
children and young people were discharged alive, and 
10% (62/627) continued to receive care at the date of 
reporting (table 2).
Patients meeting WHO preliminary case definition 
for Mis-c
Eleven per cent (52/456) of children met the WHO 
preliminary case definition for MIS-C (table 5 and 
supplementary figure F).9 The first patient identified 
developed symptoms in mid-March, when covid-19 
cases were increasing nationally, followed by a small 
number of cases identified steadily throughout the 
surveillance period (fig 3). Geographically, the highest 
number of children with MIS-C came from areas with 
the largest covid-19 outbreaks—namely, the Midlands 
and Greater London (supplementary figure G).
Children who met the WHO preliminary definition 
for MIS-C were significantly older than those who did 
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Fig 2 | Heatmap with dendrogram describing clusters (coloured) of co-occurring symptoms calculated using 
hierarchical clustering with jaccard distance as metric and complete linkage. Heatmap shows pairwise jaccard indices 
among 20 symptoms. jaccard index is measure of similarity that calculates ratio of number of times two symptoms 
appear together in data and number of times either of them appears in data. index varies between 0 and 1, with 0 
implying that two symptoms never appear together (no co-occurrence) and 1 implying that two symptoms appear 
only together (co-occurrence only). Dendrogram describing clusters of symptoms in heatmap was calculated using 
hierarchical clustering with jaccard distance as metric and complete linkage, where jaccard distance is calculated by 
subtracting jaccard index from 1. lower chest=lower chest wall indrawing
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not (median age 10.7 (8.3-14.1) v 1.6 (0.2-12.9) years; 
P<0.001) and were significantly more likely to be of 
non-white ethnicity (64% (29/45) v 42% (148/355); 
P=0.004) (table 5). MIS-C was associated with obesity 
(10% (5/51) v 2% (6/385); P=0.005) but not with 
any other comorbidity (supplementary table N). No 
children with MIS-C were admitted more than five 
days before symptom onset (table 5). In addition to the 
WHO preliminary case definition features (fever, rash, 
conjunctivitis, and gastrointestinal symptoms), the 
children with MIS-C were also more likely to present 
with fatigue (51% (24/47) v 28% (86/302); P=0.004), 
headache (34% (16/47) v 10% (26/263); P<0.001), 
myalgia (34% (15/44) v 8% (21/270); P<0.001), sore 
throat (30% (14/47) v (12% (34/284); P=0.003), 
and lymphadenopathy (20% (9/46) v 3% (10/318); 
P<0.001) than were children who did not meet MIS-C 
criteria (supplementary table O). Children with MIS-C 
also had a higher PEWS at presentation (median 5.0 
(2.8-6.2) v 3.0 (1.0-5.0); P<0.001) and were more 
likely to have reduced consciousness (25% (13/51) v 
9% (33/350); P=0.001) than those who did not meet 
the criteria (supplementary table P and supplementary 
figure H).
Children with MIS-C were five times more likely than 
others to be admitted to critical care (73% (38/52) v 15% 
(62/404); P<0.001) (table 5). They were more likely to 
receive intravenous corticosteroids (55% (24/44) v 
6% (20/353); P<0.001), non-invasive (35% (18/52) 
v 8% (31/397); P<0.001) and invasive ventilation 
(27% (14/52) v 9% (36/397); P=0.001), and inotropic 
support (51% (25/49) v 5% (18/380); P=0.001) (table 
5). Sixty five per cent (28/43) of patients with MIS-C 
received intravenous immunoglobulins, and 17% 
(7/42) received immunomodulatory therapy (three 
received anakinra, one tocilizumab, one adalimumab, 
one infliximab, and one unspecified) (supplementary 
table R). Fifty seven per cent (21/37) of MIS-C cases 
had one or more documented cardiac complications. 
Of these, 10 had impaired cardiac function on 
echocardiogram, nine had a pericardial effusion, 
three had electrocardiographic changes (heart block, 
junctional rhythm and T wave inversion, borderline 
ST elevation and changes of pericarditis), three had 
coronary artery dilatation, two had coronary artery 
aneurysm, two had myocarditis and two had valvular 
regurgitation. No deaths occurred in the MIS-C group.
Review of laboratory investigations found that 
children who met the criteria for MIS-C were more 
likely to have a platelet count of less than 150×109/L 
than those who did not (32% (16/50) v 11% (38/348); 
P<0.001) (supplementary table Q). Children who met 
the MIS-C criteria also had lower lymphocyte counts 
(median 0.9×109/L (0.7-1.7×109/L) v 2.2×109/L (1.3-
3.8×109/L); P<0.001) but higher neutrophil counts 
(8.3×109/L (5.9-12.4×109/L) v 4.6×109/L (2.3-8.6× 
109/L); P<0.001) and higher creatinine (55.0 (35.8-
82.5) μmol/L v 30.0 (20.0-51.8) μmol/L; P<0.001) 
than those without (supplementary table Q).
Of the 52 patients with MIS-C, 56% (28/50) were 
polymerase chain reaction positive for SARS-CoV-2 
(acute infection), 44% (22/50) were SARS-CoV-2 
antibody positive (post-acute), and two were confirmed 
but the method was not specified. (supplementary 
table 2 | treatments received and outcomes. values are numbers (percentages)
treatment Patients (n=651)
Antibiotic:
 No 186 (28.6)
 Yes 415 (63.7)
 Missing 50 (7.7)
Intravenous steroid:
 No 503 (77.3)
 Yes 47 (7.2)
 Missing 101 (15.5)
Oral steroid:
 No 503 (77.3)
 Yes 30 (4.6)
 Missing 118 (18.1)
Antiviral drug:
 No 553 (84.9)
 Yes 38 (5.8)
 Missing 60 (9.2)
Supplementary oxygen:
 No 455 (69.9)
 Yes 172 (26.4)
 Missing 24 (3.7)
High flow nasal cannula oxygen:
 No 536 (82.3)
 Yes 76 (11.7)
 Missing 39 (6.0)
Non-invasive ventilation:
 No 562 (86.3)
 Yes 57 (8.8)
 Missing 32 (4.9)
Invasive ventilation:
 No 562 (86.3)
 Yes 58 (8.9)
 Missing 31 (4.8)
Inotropic support:
 No 550 (84.5)
 Yes 47 (7.2)
 Missing 54 (8.3)
Nursed prone:
 No 574 (88.2)
 Yes 15 (2.3)
 Missing 62 (9.5)
Nitric oxide:
 No 583 (89.6)
 Yes 7 (1.1)
 Missing 61 (9.4)
ECMO:
 No 613 (94.2)
 Yes 2 (0.3)
 Missing 36 (5.5)
Dialysis/haemofiltration:
 No 593 (91.1)
 Yes 5 (0.8)
 Missing 53 (8.1)
ICU/HDU admission:
 No 516 (79.3)
 Yes 116 (17.8)
 Missing 19 (2.9)
Outcome
Died 6 (0.9)
Discharged alive 557 (85.6)
Ongoing care 62 (9.5)
Palliative discharge 2 (0.3)
Missing 24 (3.7)
ECMO=extracorporeal membrane oxygenation; HDU=high dependency unit; ICU=intensive care unit.
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table R). Patients with MIS-C who were antibody 
positive were younger (median age 10.0 (7.7-13.2) 
years v 12.4 (8.9-15.3) years; P=0.057) and more 
likely to be of non-white ethnicity (90% (19/21) v 45% 
(10/22); P=0.003) than those who were polymerase 
chain reaction positive. Although obesity had been 
associated with MIS-C (table 5), when analysed by 
SARS-CoV-2 detection method this feature seemed to 
be driven by those with MIS-C who were polymerase 
chain reaction positive, as none of the antibody 
positive patients were obese (19% (5/27) v 0% (0/22); 
P=0.056) (supplementary table S).
On comparing presenting symptoms, we found that 
conjunctivitis (71% (15/21) v 16% (4/25); P<0.001) 
and abdominal pain (95% (20/21) v 44% (12/27); 
P<0.001) were more common in patients who were in 
the antibody positive group, whereas those in the acute 
phase of infection and positive by polymerase chain 
reaction were more likely to present with shortness 
of breath (52% (14/27) v 14% (3/21); P=0.014) 
(supplementary table T).
Although PEWS was similar between the groups, 
children who were polymerase chain reaction posi-
tive were more likely to have a need for oxygen at 
table 3 | Demographics stratified by admission to critical care. values are numbers (percentages) unless stated 
otherwise
variable
standard ward admission  
(n=516; 81.6%)
critical care admission  
(n=116; 18.4%) P value*
Median (interquartile range) age, years 3.7 (0.3-13.8) 8.9 (0.4-13.5) 0.29
Neonate (<1 month): 0.007
 No 482 (93.4) 99 (85.3)
 Yes 34 (6.6) 17 (14.7)
Age group, years: <0.001
 <1 186 (36.0) 31 (26.7)
 1-4 90 (17.4) 15 (12.9)
 5-9 73 (14.1) 18 (15.5)
 10-14 58 (11.2) 33 (28.4)
 15-19 109 (21.1) 19 (16.4)
Sex at birth: 0.300
 Male 286 (55.4) 71 (61.2)
 Female 229 (44.4) 45 (38.8)
 Missing 1 (0.2) 0 (0.0)
Ethnicity: 0.001
 White 282 (54.7) 41 (35.3)
 Black 36 (7.0) 19 (16.4)
 South Asian 49 (9.5) 13 (11.2)
 Other 92 (17.8) 26 (22.4)
 Missing 57 (11.0) 17 (14.7)
Admitted >5 days before symptom onset: 0.009
 No 437 (84.7) 92 (79.3)
 Yes 36 (7.0) 18 (15.5)
 Missing 43 (8.3) 6 (5.2)
Any comorbidity: 0.009
 No/unknown 306 (59.3) 53 (45.7)
 Yes 210 (40.7) 63 (54.3)
Prematurity†: 0.001
 No 135 (26.2) 15 (12.9)
 Yes 30 (5.8) 15 (12.9)
 Missing 351 (68.0) 86 (74.1)
Respiratory comorbidity: 0.019
 No 470 (91.1) 103 (88.8)
 Yes 21 (4.1) 12 (10.3)
 Missing 25 (4.8) 1 (0.9)
Cardiac comorbidity: 0.018
 No 468 (90.7) 102 (87.9)
 Yes 25 (4.8) 13 (11.2)
 Missing 23 (4.5) 1 (0.9)
Obesity: 0.028
 No 477 (92.4) 108 (93.1)
 Yes 10 (1.9) 7 (6.0)
 Missing 29 (5.6) 1 (0.9)
Immunosuppressant use before presentation‡: 1.00
 No 443 (85.9) 101 (87.1)
 Yes 43 (8.3) 10 (8.6)
 Missing 30 (5.8) 5 (4.3)
*Categorical variables analysed using Fisher’s exact test and continuous variables by Kruskal-Wallis test.
†Defined as birth before completion of 37 weeks’ gestation.
‡Includes oral but not inhaled corticosteroids.
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presentation (40% (10/25) v 14% (3/22); P=0.056) 
(supplementary table U). Blood results at presentation 
were similar between the two groups, with the 
exception of prothrombin time, which was longer in 
the group who were polymerase chain reaction positive 
(median 14.8 (13.4-15.8) sec v 11.6 (11.0-12.0) sec; 
P=0.013) (supplementary table V).
Treatments received also differed between the two 
groups, with patients who were antibody positive 
being more likely to receive intravenous steroids (84% 
(16/19) v 35% (8/23); P=0.002) and intravenous 
immunoglobulin (86% (19/22) v 43% (9/21); 
P=0.004) than those who were polymerase chain 
reaction positive (supplementary table R). The need for 
critical care or respiratory or cardiovascular support 
did not differ between the two groups. Although 
cardiac complications were seen in both groups, 
they were more frequent in patients with MIS-C who 
were antibody positive (75% (15/20) v 35% (6/17); 
P=0.022) (supplementary table R).
discussion
Six hundred and fifty one children and young people 
aged under 19 years with laboratory confirmed 
SARS-CoV-2 were recruited to the ISARIC WHO 
CCP-UK study between 17 January and 3 July 2020, 
accounting for 0.9% of all patients in the whole 
cohort at that time. The median age of children with 
covid-19 was 4.6 (interquartile range 0.3–13.7) 
years. The cohort was predominantly male (56%) 
and of white ethnicity (57%), with most (58%) 
children having no known comorbidities. The 
most common presenting symptoms were fever, 
cough, shortness of breath, nausea, and vomiting, 
and a systemic mucocutaneous-enteric cluster of 
symptoms was seen. Eighteen per cent of children 
admitted to hospital needed critical care. Critical 
care admission was associated with age younger than 
1 month, age 10-14 years, and black ethnicity. The 
all cause in-hospital case fatality rate for children 
and young people was strikingly low at 1% (6/627), 
compared with 27% (18 803/69 516) in the whole 
cohort of all ages (0-106 years) over the same time 
period. In this paediatric cohort, 11% of children 
and young people met the WHO preliminary criteria 
for MIS-C, which was associated with older age, 
non-white ethnicity, and admission to critical care. 
MIS-C cases were first identified in mid-March when 
cases of covid-19 began to rise in the UK. In addition 
to the clinical criteria provide by WHO,9 we found 
that children with MIS-C were more likely to present 
with fatigue, headache, myalgia, sore throat, and 
lymphadenopathy, as well as a lower platelet count 
than children with SARS-CoV-2 who did not meet the 
MIS-C criteria.
Children who had been admitted to hospital for 
more than five days before symptom onset were 
also more likely to be admitted to critical care. 
By definition, this group includes children with 
comorbidity, which was associated with critical care 
admission. SARS-CoV-2 nosocomial infections in 
children are not well reported, and this area warrants 
closer scrutiny, ideally with the use of viral sequence 
data.
This study identified children meeting the criteria for 
MIS-C in both the acute phase of infection (polymerase 
chain reaction positive) and post-acute or convalescent 
phase of infection (antibody positive) groups. Although 
the two groups shared many similarities, important 
differences included the post-acute group being more 
strongly associated with non-white ethnicity and 
muco-enteric symptom presentation (abdominal pain 
and conjunctivitis), whereas the acute group presented 
more commonly with respiratory symptoms. Cardiac 
complications occurred across both groups but were 
more common in the post-acute patients, who were 
also more likely to receive intravenous steroids and 
immunoglobulins.
table 4 | Factors associated with admission to critical care unit. values are numbers (percentages) unless stated otherwise
variable
standard ward admission 
(n=516; 81.6%)
critical care admission 
(n=116; 18.4%)
Odds ratio (95% ci)
univariable Multivariable
Sex at birth:
 Male 286 (80.1) 71 (19.9) - -
 Female 229 (83.6) 45 (16.4) 0.79 (0.52 to 1.19); P=0.266 0.82 (0.51 to 1.31); P=0.405
Age group:
 15-19 years 109 (85.2) 19 (14.8) - -
 <1 month 34 (66.7) 17 (33.3) 2.87 (1.34 to 6.16); P=0.007 3.21 (1.36 to 7.66); P=0.008
 1 month to <1 year 152 (91.6) 14 (8.4) 0.53 (0.25 to 1.09); P=0.088 0.53 (0.22 to 1.25); P=0.151
 1-4 years 89 (85.6) 15 (14.4) 0.97 (0.46 to 2.01); P=0.928 1.28 (0.57 to 2.89); P=0.545
 5-9 years 73 (80.2) 18 (19.8) 1.41 (0.69 to 2.89); P=0.338 1.33 (0.58 to 3.05); P=0.493
 10-14 years 58 (63.7) 33 (36.3) 3.26 (1.72 to 6.33); P<0.001 3.23 (1.55 to 6.99); P=0.002
Ethnicity:
 White 281 (87.3) 41 (12.7) - -
 Black 36 (65.5) 19 (34.5) 3.62 (1.88 to 6.86); P<0.001 2.82 (1.41 to 5.57); P=0.003
 South Asian 49 (79.0) 13 (21.0) 1.82 (0.88 to 3.56); P=0.091 1.86 (0.87 to 3.77); P=0.094
 Other 92 (78.0) 26 (22.0) 1.94 (1.11 to 3.32); P=0.017 1.91 (1.07 to 3.34); P=0.025
Any comorbidity:
 No/unknown 305 (85.2) 53 (14.8) - -
 Yes 210 (76.9) 63 (23.1) 1.73 (1.15 to 2.60); P=0.008 1.42 (0.89 to 2.28); P=0.141
Univariable and multivariable logistic regression analyses used potential predictors identified a priori and during exploratory analyses.
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table 5 | Demographics at presentation and therapies administered stratified by multisystem inflammatory syndrome in 
children and adolescents (Mis-c) status. values are numbers (percentage) unless stated otherwise
variable
Did not meet Mis-c criteria  
(n=404; 88.6%)
Met Mis-c criteria  
(n=52; 11.4%) P value*
Median (interquartile range) age, years 1.6 (0.2 to 12.9) 10.7 (8.3 to 14.1) <0.001
Age group, years: <0.001
 <1 164 (40.6) 1 (1.9)
 1-4 70 (17.3) 4 (7.7)
 5-9 43 (10.6) 16 (30.8)
 10-14 48 (11.9) 22 (42.3)
 15-19 79 (19.6) 9 (17.3)
Sex at birth: 1.00
 Male 241 (59.7) 31 (59.6)
 Female 163 (40.3) 21 (40.4)
 Missing 0 (0.0) 0 (0.0)
Ethnicity: 0.004
 White 207 (51.2) 16 (30.8)
 Black 30 (7.4) 9 (17.3)
 South Asian 44 (10.9) 4 (7.7)
 Other 74 (18.3) 16 (30.8)
 Missing 49 (12.1) 7 (13.5)
White ethnicity: 0.004
 No 148 (36.6) 29 (55.8)
 Yes 207 (51.2) 16 (30.8)
 Missing 49 (12.1) 7 (13.5)
Any comorbidity: 0.052
 No/unknown 227 (56.2) 37 (71.2)
 Yes 177 (43.8) 15 (28.8)
Obesity: 0.005
 No 379 (93.8) 46 (88.5)
 Yes 6 (1.5) 5 (9.6)
 Missing 19 (4.7) 1 (1.9)
Immunosuppressant use before presentation†: 0.60
 No 348 (86.1) 48 (92.3)
 Yes 35 (8.7) 3 (5.8)
 Missing 21 (5.2) 1 (1.9)
Admitted >5 days before symptom onset: 0.014
 No 345 (85.4) 52 (100.0)
 Yes 35 (8.7) 0 (0.0)
 Missing 24 (5.9) 0 (0.0)
Intravenous steroid: <0.001
 No 333 (82.4) 20 (38.5)
 Yes 20 (5.0) 24 (46.2)
 Missing 51 (12.6) 8 (15.4)
High flow nasal cannula oxygen: <0.001
 No 343 (84.9) 29 (55.8)
 Yes 47 (11.6) 23 (44.2)
 Missing 14 (3.5) 0 (0.0)
Non-invasive ventilation: <0.001
 No 366 (90.6) 34 (65.4)
 Yes 31 (7.7) 18 (34.6)
 Missing 7 (1.7) 0 (0.0)
Invasive ventilation: 0.001
 No 361 (89.4) 38 (73.1)
 Yes 36 (8.9) 14 (26.9)
 Missing 7 (1.7) 0 (0.0)
Inotropic support: <0.001
 No 362 (89.6) 24 (46.2)
 Yes 18 (4.5) 25 (48.1)
 Missing 24 (5.9) 3 (5.8)
ICU/HDU admission: <0.001
 No 342 (84.7) 14 (26.9)
 Yes 62 (15.3) 38 (73.1)
 Missing 0 (0.0) 0 (0.0)
Outcome: 0.49
 Died 4 (1.0) 0 (0.0)
 Discharged alive 353 (87.4) 43 (82.7)
 Ongoing care 37 (9.2) 8 (15.4)
 Palliative discharge 2 (0.5) 0 (0.0)
 Missing 8 (2.0) 1 (1.9)
HDU=high dependency unit; ICU=intensive care unit.
*Categorical variables analysed using Fisher’s exact test and continuous variables by Kruskal-Wallis test.
†Includes oral but not inhaled corticosteroids.
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strengths and limitations of study
This study is unique in that data for patients with 
laboratory confirmed covid-19 were collected pros-
pectively and throughout the admission. The ISARIC 
WHO CCP-UK study had previously been activated in 
2016 and 2018 for cases of Middle East respiratory 
syndrome (MERS) and monkeypox, and so was 
prepared for the SARS-CoV-2 pandemic, allowing swift 
activation. Consequently, in addition to reporting the 
clinical characteristics, risk factors, and outcomes of 
covid-19 in children, this dataset provided a unique 
opportunity to objectively monitor the emergence 
and progression of a novel multisystem inflammatory 
syndrome in the UK, while minimising recall bias. 
The first patient meeting the criteria for MIS-C was 
identified on 20 March 2020, and the first published 
cases were reported on 6 May 2020.8 Comparison 
with overall covid-19 cases confirms the sporadic 
occurrence of MIS-C throughout the first peak of the 
covid-19 pandemic in the UK. In contrast to previous 
reports, our analysis was limited to children admitted 
with laboratory confirmed SARS-CoV-2, which allowed 
us to clearly define the picture of covid-19 in children 
and reduce confounding by other potential causes.
The ISARIC WHO CCP-UK database was estimated to 
represent two thirds of hospital admissions for covid-19 
across England, Wales, and Scotland at the time of 
extraction. It is therefore susceptible to selection bias, 
particularly as tertiary centres with critical care units 
and specialist children’s hospitals are more likely to 
have dedicated research teams, potentially skewing 
the severity and age of the patients reported. The most 
common presenting symptoms in children in our study 
(fever, cough, and dyspnoea) reflect the original case 
definition for SARS-CoV-2 testing in the UK, suggesting 
that this paediatric cohort is likely to have been 
influenced by the testing criteria.
The PEWS is validated up to 16 years of age.14 As 
ranges of clinical observations do not vary much 
between 16 and 18 year olds,20 PEWS scoring was 
extended to all those under 19 years. To identify 
children and young people meeting the WHO criteria 
for MIS-C, data on C reactive protein and fever are 
needed. Decisions to measure C reactive protein and 
other parameters were at physicians’ discretion. 
Children missing either of these variables were 
excluded from this analysis.
A limitation of this study is the use of a case record 
form that was agnostic to age and so not specifically 
tailored for paediatric data collection, particularly 
regarding comorbidities. Some of this information was 
available in free text, but these data were incomplete. 
By design, we were not able to differentiate between 
people whose symptoms were directly attributable 
to SARS-CoV-2 infection and those who had been 
admitted for other reasons and then found to be positive 
for the virus. The study relied primarily on polymerase 
chain reaction testing as evidence of SARS-CoV-2 
infection, as diagnostic serology was not available at 
the start of the pandemic. This could have limited early 
recruitment of MIS-C cases. Finally, in order to share 
findings from this study promptly as an urgent public 
health research priority, these analyses were performed 
on a cohort with ongoing data collection and missing 
data, the proportion of which will decrease with time. 
This may affect our estimate of the incidence of MIS-C 
at 11% (52/456) among children and young people 
with proven SARS-CoV-2 infection, which is calculated 
on the 70% (456/651) who had data available for fever 
and C reactive protein, thus allowing WHO preliminary 
criteria to be applied. Children without features of 
MIS-C or sepsis are not likely to have their clotting 
and inflammatory markers measured, so reducing the 
pool of complete data and the denominator. We do 
not have data for children identified as infected with 
SARS-CoV-2 in the community who were not admitted 
to hospital, and we cannot yet report on sequelae of 
covid-19 in children after discharge.
comparison with other studies
Children and young people aged under 19 years 
accounted for 0.9% (651/69 516) of the ISARIC WHO 
CCP-UK cohort on 3 July 2020, which is broadly 
consistent with 2% reported in China and 1.7% in 
North America.1 2 Our cohort of paediatric patients 
admitted to hospital had a median age of 4.6 years, 
NoYes
Date of symptom onset
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Fig 3 | Dates of symptom onset for paediatric cases of sars-cov-2 infection and cases meeting WHO preliminary 
criteria for multisystem inflammatory syndrome in children and adolescents (Mis-c) in isaric WHO ccP-uK cohort 
over time
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which was similar to an Italian cohort (3.3 years21), 
but younger than Chinese (6-7 years5 6) and North 
American (11 years2) cohorts; however, these other 
cohorts were not limited to children admitted to 
hospital. Although respiratory presentations were most 
common, 35% of children also had gastrointestinal 
symptoms at presentation, which is higher than the 
10-22% reported in other paediatric literature.2 21 22 
Gastrointestinal symptoms have also been prominent 
in children presenting with infection by MERS-
CoV (28%) and severe acute respiratory syndrome 
coronavirus (SARS-CoV) (30%).23 24 We also identified 
a distinct systemic mucocutaneous-enteric cluster of 
symptoms in the acute phase of SARS-CoV-2 infection, 
which shows overlap with the WHO preliminary case 
definition for MIS-C.
Children of black ethnicity were over-represented, 
comprising 10% of our paediatric cohort compared 
with a population representation of 4.7% of all children 
under 18 years across England and Wales and 1% in 
Scotland.25 26 This finding may also be influenced by 
the ethnic composition of the population served by 
the sites recruiting to this study. Black ethnicity was 
also associated with increased odds of admission to 
critical care on multivariable analysis, consistent with 
reports for adult populations suggesting that South 
Asian and black ethnicities are disproportionately 
severely affected by SARS-CoV-2 infection.27-29 Studies 
of paediatric covid-19 from other countries either 
have been from ethnically homogenous groups or 
have not reported ethnicity, making comparisons 
difficult.
The rate of admission to critical care in our cohort 
was 18%, compared with 10% reported in a North 
American cohort of children admitted to hospital 
and 13% in a multicentre cohort study across 25 
European countries.2 22 As previously noted, this rate 
may be elevated in our study owing to hospitals with 
dedicated paediatric research teams being more likely 
to provide paediatric critical care. The prevalence of 
comorbidities (54%) in children admitted to critical 
care in our cohort was also similar to that reported 
in the European multicentre study (52%).22 Obesity 
was associated with critical care admission in our 
paediatric cohort, in agreement with adult data from 
ISARIC WHO CCP-UK.13 In England, 20% of children 
are obese by 11 years of age.30 Childhood obesity, 
however, is also influenced by deprivation,30 which 
we did not analyse in our study. Age under 1 month 
was associated with increased odds of critical care 
admission, in agreement with the European cohort.22 
Thirty five per cent of children in our study were 
under 1 year old, which may reflect a low threshold 
for admissions of infants by clinicians rather than 
severe concerns about their clinical condition. This 
may explain the predominance of younger children 
in our study. In addition, the association between age 
under 1 month and admission to critical care might 
be explained if these babies were already admitted to 
neonatal intensive care and undergoing regular SARS-
CoV-2 screening.
Using adapted WHO criteria,9 we identified 52 
patients meeting the criteria for multisystem inflam-
matory syndrome. Initial UK reports described children 
admitted to hospital with circulatory shock and a 
hyperinflammatory state with features similar to toxic 
shock or Kawasaki disease.8 Children fulfilling the case 
definition for MIS-C have been reported in multiple 
regions experiencing large outbreaks of covid-19, 
including England (UK),31 Paris (France),11 Bergamo 
(Italy),10 and New York City (USA).32 Ours is the first 
report, however, to identify cases and timelines by using 
a prospective national data collection strategy. MIS-C 
seems to be temporally associated with covid-19, but 
a causal relation remains to be established. Older age 
and non-white ethnicity were associated with MIS-C in 
our study, in agreement with a recent case series of 99 
children with MIS-C from New York State (USA), where 
63% were of non-white ethnicity and 69% were aged 
between 6 and 20 years.32 Children in our study with 
MIS-C were much more unwell than other children 
with covid-19, with 51% needing inotropic support, 
compared with 20% in the Italian cohort,10 47% in the 
French cohort,11 and 62% in the New York cohort.29
It is becoming apparent that MIS-C can present 
both in children with acute SARS-CoV-2 infection and 
in the post-acute or convalescent phase of infection. 
A large case series of 565 children with MIS-C 
across North America has been recently reported 
by the Centers for Disease Prevention and Control 
(CDC), which used latent class analysis to identify 
three classes of MIS-C.33 Class 1 predominantly 
comprises patients who were antibody positive and 
polymerase chain reaction negative for SARS-CoV-2, 
with multiple systems involved, a strong association 
with cardiac complications, and a greater likelihood 
of having received intravenous immunoglobin and 
corticosteroids. These class 1 patients resemble the 
post-acute group in our analysis. The CDC describes 
class 2 as children who were predominantly poly-
merase chain reaction positive with more respiratory 
involvement, and these resemble the acute group in 
our analysis.
We believe that the characterisation of SARS-CoV-2 
illness in children into polymerase chain reaction 
positive versus serology positive as distinct entities is 
likely to be an oversimplification. Instead, our data 
suggest that clinical presentation varies at different 
time points in the course of SARS-CoV-2 infection and 
immune response.
Across the whole of our paediatric cohort, we 
identified a distinct cluster presenting with syste mic 
mucocutaneous-enteric symptoms (rash, conjunc-
tivitis, diarrhoea, vomiting, and abdominal pain) in 
addition to headache, myalgia, sore throat, fatigue, 
and lymphadenopathy, which overlapped closely with 
the WHO preliminary case definition.9
MIS-C can present in both the acute and convalescent 
phases of SARS-CoV-2 infection. The significant 
associations between MIS-C and fatigue, headache, 
myalgia, sore throat, and lymphadenopathy in our 
cohort may be useful in refining the case definition. 
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In addition, the association of MIS-C with platelet 
count less than 150×109/L and low lymphocyte counts 
agrees with previous reports.31 32 These important 
findings may assist in differentiating this syndrome 
from other illnesses, particularly Kawasaki disease in 
which platelet counts are typically elevated.
conclusion and policy implications
Our data confirm less severe covid-19 in children 
and young people with SARS-CoV-2 infection than 
in adults. Admission to critical care was associated 
with age under 1 month, age 10-14 years, and black 
ethnicity. In agreement with previous reports, we found 
older age and non-white ethnicity to be associated with 
MIS-C.
We also report that patients with MIS-C who are 
antibody positive for SARS-CoV-2 are more likely 
to be of non-white ethnicity, have mucocutaneous-
enteric symptoms and cardiac complications, and 
have received intravenous immunoglobulins and 
corticosteroids than those who are in the acute phase 
of infection (polymerase chain reaction positive).
We have identified a systemic mucocutaneous-
enteric symptom cluster across the whole cohort. 
In addition, we have provided evidence for refining 
the WHO case definition for MIS-C, including an 
association with low platelet count, fatigue, headache, 
myalgia, sore throat, and lymphadenopathy.
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